

AMENDMENTS TO THE CLAIMS

The following claims will replace all prior versions and listings of claims in this application.

1. (Currently amended) A method for producing a ~~human-like~~ recombinant glycoprotein comprising a desired N-glycan in a lower eukaryotic host cell comprising the step of expressing in the host cell a nucleic acid encoding a mannosidase ~~enzymatic activity~~ enzyme that is capable of hydrolyzing *in vivo* an oligosaccharide substrate comprising either or both a Man α 1,3 and Man α 1,6 glycosidic linkage to the extent that at least 10% of the Man α 1,3 and/or Man α 1,6 linkages of the substrate are hydrolyzed *in vivo*.
2. (Currently amended) A method for producing recombinant glycoprotein comprising a desired N-glycan in a lower eukaryotic host cell comprising the step of expressing in the host cell a nucleic acid encoding a mannosidase ~~enzymatic activity~~ enzyme that is capable of hydrolyzing *in vivo* an oligosaccharide substrate comprising either or both a Man α 1,3 and Man α 1,6 glycosidic linkage wherein the desired N-glycan is produced within the host cell at a yield of at least 10 mole percent.
3. (Currently amended) The method of claim 1 or 2, wherein the desired N-glycan produced is selected from the group consisting of Man₃GlcNAc₂, GlcNAcMan₃GlcNAc₂ and Man₄GlcNAc₂.
4. (Currently amended) The method of claim 1 or 2, wherein the desired N-glycan is characterized as having at least the oligosaccharide branch Man α 1,3 (Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn.
5. (Currently amended) The method of claim 1 or 2, wherein the mannosidase ~~enzymatic activity~~ enzyme is capable of hydrolyzing *in vivo* both Man α 1,3 and Man α 1,6 linkages of an oligosaccharide substrate comprising a Man α 1,3 and Man α 1,6 glycosidic linkage.
6. (Original) The method of claim 1 or 2, wherein the oligosaccharide substrate is characterized as Man α 1,3 (Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; Man α 1,3 (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; GlcNAc β 1,2 Man α 1,3 (Man α 1,6

Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; GlcNAc β 1,2 Man α 1,3 (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; Man α 1,3 (Man α 1,3 Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; GlcNAc β 1,2 Man α 1,3 (Man α 1,3 Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; Man α 1,2 Man α 1,3 (Man α 1,3 Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; Man α 1,2 Man α 1,3 (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; Man α 1,2 Man α 1,3 (Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn or high mannan.

7. (Currently amended) The method of claim 1 or 2, wherein the mannosidase activity enzyme is ~~characterized as~~ a Class 2 mannosidase activity enzyme.

8. (Currently amended) The method of claim 7, wherein the Class 2 mannosidase activity enzyme has a substrate specificity for GlcNAc β 1,2 Man α 1,3 (Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; GlcNAc β 1,2 Man α 1,3 (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; or GlcNAc β 1,2 Man α 1,3 (Man α 1,3 Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn.

9. (Currently amended) The method of claim 7, wherein the Class 2 mannosidase activity enzyme is one which is normally found in the Golgi apparatus of a higher eukaryotic host cell.

10. (Currently amended) The method of claim 1 or 2, wherein the mannosidase activity enzyme is ~~characterized as~~ a Class IIx mannosidase activity.

11. (Currently amended) The method of claim 10, wherein the Class IIx mannosidase activity enzyme has a substrate specificity for Man α 1,3 (Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; Man α 1,3 (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; or Man α 1,2 Man α 1,3 (Man α 1,3 Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn.

12. (Currently amended) The method of claim 1 or 2, wherein the mannosidase activity enzyme is ~~characterized as~~ a Class III mannosidase activity.

13. (Currently amended) The method of claim 12, wherein the Class III mannosidase activity enzyme has a substrate specificity for (Man α 1,6 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; (Man α 1,3 Man α 1,6) Man β 1,4-GlcNAc β 1,4-GlcNAc-Asn; or high mannans.

14. (Currently amended) The method of claim 1 or 2, wherein the mannosidase ~~activity~~ enzyme is overexpressed.

15. (Currently amended) The method of claim 1 or 2, wherein the mannosidase enzyme is further capable of hydrolyzing a Man α 1,2 linkage.

16. (Currently amended) The method of claim 1 or 2, wherein the mannosidase ~~activity~~ enzyme has a pH optimum of from about 5.0 to about 8.0.

17. (Currently amended) The method of claim 1 or 2, wherein the mannosidase enzyme is further capable of hydrolyzing a Man α 1,2 linkage.

18. (Currently amended) The method of claim 1 or 2, wherein the mannosidase ~~activity~~ enzyme is localized within the secretory pathway of the host cell.

19. (Currently amended) The method of claim 1 or 2, wherein the mannosidase ~~activity~~ enzyme is ~~expressed from a polypeptide localized~~ localized within at least one of the ER, Golgi apparatus or the trans ~~golgi~~ Golgi network of the host cell.

20. (Currently amended) The method of claim 1 or 2, wherein the nucleic acid encoding the mannosidase ~~activity is expressed from a nucleic acid encoding a polypeptide~~ enzyme encodes an enzyme comprising a mannosidase catalytic domain fused to a ~~cellular~~ targeting ~~signal~~ peptide.

21. (Currently amended) The method of claim 20, wherein the ~~mannosidase activity is expressed from a nucleic acid comprising sequences that encode a~~ mannosidase catalytic domain is native to the host cell.

22. (Currently amended) The method of claim 20, wherein the ~~mannosidase activity is expressed from a nucleic acid comprising sequences that encode a~~ mannosidase catalytic domain is heterologous to the host cell.

23. (Currently amended) The method of claim 1 or 2, wherein the mannosidase ~~enzymatic activity~~ enzyme is selected from the group consisting of *Arabidopsis thaliana* Mannosidase II, *C. elegans* Mannosidase II, *Ciona intestinalis* mannosidase II, *Drosophila*

mannosidase II, Human mannosidase II, Mouse mannosidase II, Rat mannosidase II, Human mannosidase IIx, Insect cell mannosidase III, Human lysosomal mannosidase II and Human cytoplasmic mannosidase II.

24. (Currently amended) The method of claim ~~20~~ ~~1 or 2~~, wherein the ~~polypeptide is expressed from a nucleic acid comprising sequences that encode a target~~ targeting peptide is native to the host cell.

25. (Currently amended) The method of claim ~~20~~ ~~1 or 2~~, wherein the ~~polypeptide is expressed from a nucleic acid comprising sequences that encode a target~~ targeting peptide is heterologous to the mannosidase catalytic domain.

26. (Original) The method of claim 1 or 2, further comprising the step of isolating the glycoprotein from the host cell.

27. (Original) The method of claim 1 or 2, wherein the host cell is selected from the group consisting of *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, *Pichia koclamae*, *Pichia membranaefaciens*, *Pichia opuntiae*, *Pichia thermotolerans*, *Pichia salictaria*, *Pichia guercuum*, *Pichia pijperi*, *Pichia stiptis*, *Pichia methanolica*, *Pichia sp.*, *Saccharomyces cerevisiae*, *Saccharomyces sp.*, *Hansenula polymorpha*, *Kluyveromyces sp.*, *Kluyveromyces lactis*, *Candida albicans*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Trichoderma reesei*, *Chrysosporium lucknowense*, *Fusarium sp.*, *Fusarium gramineum*, *Fusarium venenatum* and *Neurospora crassa*.

28. (Original) The method of claim 27, wherein the host cell is *Pichia pastoris*.

29. (Original) The method of claim 1 or 2, wherein the glycoprotein is a therapeutic protein.

30. (Original) The method of claim 29, wherein the therapeutic protein is selected from the group consisting of erythropoietin, cytokines, coagulation factors, soluble IgE receptor α -chain, IgG, IgG fragments, IgM, interleukins, urokinase, chymase, urea trypsin inhibitor, IGF-binding protein, epidermal growth factor, growth hormone-releasing factor, annexin V fusion

protein, angiostatin, vascular endothelial growth factor-2, myeloid progenitor inhibitory factor-1, osteoprotegerin, α -1-antitrypsin and α - feto protein.

31– 56. (Cancelled)